Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel Free BDTX Stock Alerts

Black Diamond Therapeutics (BDTX) Financials

Black Diamond Therapeutics logo
$1.73 -0.03 (-1.70%)
Closing price 07/27/2026 04:00 PM Eastern
Extended Trading
$1.75 +0.02 (+1.16%)
As of 07/27/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Black Diamond Therapeutics

Annual Income Statements for Black Diamond Therapeutics

This table shows Black Diamond Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -8.93 -35 -65 -126 -91 -82 -70 22
Consolidated Net Income / (Loss)		 -8.93 -41 -67 -126 -91 -82 -70 22
Net Income / (Loss) Continuing Operations		 -8.93 -41 -65 -126 -91 -82 -70 22
Total Pre-Tax Income 		-8.93 -35 -67 -126 -89 -82 -70 22
Total Operating Income		 -8.90 -29 -70 -127 -93 -86 -79 13
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 70
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 70
Operating Revenue		 - - - - - - 0.00 70
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 8.90 29 70 127 93 86 79 57
Selling, General & Admin Expense		 1.95 7.58 21 30 28 27 27 17
Research & Development Expense		 6.95 22 48 97 64 59 51 34
Impairment Charge		 - - - - - - 0.00 7.35
Total Other Income / (Expense), net		 -0.03 -5.93 2.32 1.28 3.91 4.02 9.11 9.85
Interest & Investment Income		 0.00 0.46 4.04 3.46 2.03 1.92 2.18 4.06
Other Income / (Expense), net		 -0.03 -6.39 -1.72 -2.19 1.88 2.09 6.92 5.78
Basic Earnings per Share		 ($4.42) ($16.99) ($2.05) ($3.47) ($2.52) ($1.88) ($1.27) $0.39
Weighted Average Basic Shares Outstanding		 2.02M 2.08M 32.91M 36.19M 36.33M 43.95M 55.03M 56.87M
Diluted Earnings per Share		 ($4.42) ($16.99) ($2.05) ($3.47) ($2.52) ($1.88) ($1.27) $0.39
Weighted Average Diluted Shares Outstanding		 2.02M 2.08M 32.91M 36.19M 36.33M 43.95M 55.03M 57.56M
Weighted Average Basic & Diluted Shares Outstanding		 2.02M 2.08M 32.91M 36.27M 36.48M 51.72M 56.66M 57.29M

Quarterly Income Statements for Black Diamond Therapeutics

This table shows Black Diamond Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -23 -19 -18 -20 -16 -16 57 -11 -8.50 -15 -9.04
Consolidated Net Income / (Loss)		 -23 -19 -18 -20 -16 -16 57 -11 -8.50 -15 -9.04
Net Income / (Loss) Continuing Operations		 -23 -19 -18 -20 -16 -16 57 -11 -8.50 -15 -9.04
Total Pre-Tax Income 		-23 -19 -18 -20 -16 -16 57 -11 -8.50 -15 -9.04
Total Operating Income		 -24 -21 -20 -22 -18 -18 55 -13 -11 -18 -11
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 70 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 70 0.00 0.00 - 0.00
Operating Revenue		 - - 0.00 0.00 0.00 - 70 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 24 21 20 22 18 18 15 13 11 18 11
Selling, General & Admin Expense		 7.86 5.57 6.70 9.57 5.22 5.98 4.96 4.10 3.54 3.97 4.26
Research & Development Expense		 16 15 14 13 13 12 11 9.32 7.44 6.30 7.00
Total Other Income / (Expense), net		 1.01 1.45 2.02 2.22 2.57 2.29 2.01 2.86 2.48 2.49 2.22
Interest & Investment Income		 0.44 0.32 0.64 0.46 0.52 0.57 0.60 1.12 1.16 1.18 1.02
Other Income / (Expense), net		 0.57 1.12 1.38 1.76 2.06 1.73 1.42 1.74 1.32 1.31 1.20
Basic Earnings per Share		 ($0.45) ($0.34) ($0.35) ($0.36) ($0.28) ($0.28) $1.00 ($0.19) ($0.15) ($0.27) ($0.16)
Weighted Average Basic Shares Outstanding		 50.94M 43.95M 51.81M 55.16M 56.51M 55.03M 56.66M 56.80M 56.93M 56.87M 57.23M
Diluted Earnings per Share		 ($0.45) ($0.34) ($0.35) ($0.36) ($0.28) ($0.28) $0.98 ($0.19) ($0.15) ($0.25) ($0.16)
Weighted Average Diluted Shares Outstanding		 50.94M 43.95M 51.81M 55.16M 56.51M 55.03M 57.67M 56.80M 56.93M 57.56M 57.23M
Weighted Average Basic & Diluted Shares Outstanding		 51.64M 51.72M 56.25M 56.50M 56.59M 56.66M 56.86M 56.94M 56.97M 57.29M 57.30M

Annual Cash Flow Statements for Black Diamond Therapeutics

This table details how cash moves in and out of Black Diamond Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 44 103 -119 31 -32 22 -20 -15
Net Cash From Operating Activities		 -8.45 -25 -52 -100 -85 -67 -62 30
Net Cash From Continuing Operating Activities		 -8.47 -25 -52 -100 -85 -67 -62 30
Net Income / (Loss) Continuing Operations		 -8.93 -35 -67 -126 -91 -82 -70 22
Consolidated Net Income / (Loss)		 -8.93 -35 -67 -126 -91 -82 -70 22
Depreciation Expense		 0.04 0.05 0.05 0.21 0.51 0.44 0.34 0.33
Amortization Expense		 - 0.00 1.73 2.19 0.54 -1.17 -3.78 -1.28
Non-Cash Adjustments To Reconcile Net Income		 0.06 3.68 8.29 16 15 13 14 17
Changes in Operating Assets and Liabilities, net		 0.34 6.86 5.04 7.02 -9.90 3.69 -2.69 -8.73
Net Cash From Investing Activities		 -0.08 -0.02 -282 131 53 16 17 -45
Net Cash From Continuing Investing Activities		 -0.08 -0.02 -282 131 53 16 17 -45
Purchase of Investments		 - 0.00 -372 -50 -60 -62 -123 -164
Sale of Property, Plant & Equipment		 - - - 0.00 0.01 0.10 0.09 0.03
Sale and/or Maturity of Investments		 - 0.00 91 183 114 78 140 119
Net Cash From Financing Activities		 52 128 215 0.73 0.18 72 26 -0.15
Net Cash From Continuing Financing Activities		 52 128 215 0.73 0.18 72 26 -0.15
Issuance of Common Equity		 - 0.00 214 - 0.18 72 24 0.00
Other Financing Activities, net		 - 0.00 1.10 0.73 - - 1.05 -0.15

Quarterly Cash Flow Statements for Black Diamond Therapeutics

This table details how cash moves in and out of Black Diamond Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 16 -1.75 -31 7.39 -9.38 13 62 -68 0.87 -9.87 9.08
Net Cash From Operating Activities		 -18 -14 -21 -15 -11 -15 53 -9.16 -7.85 -6.79 -10
Net Cash From Continuing Operating Activities		 -18 -14 -21 -15 -11 -15 53 -9.16 -7.85 -6.79 -10
Net Income / (Loss) Continuing Operations		 -23 -19 -18 -20 -16 -16 57 -11 -8.50 -15 -9.04
Consolidated Net Income / (Loss)		 -23 -19 -18 -20 -16 -16 57 -11 -8.50 -15 -9.04
Depreciation Expense		 0.12 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.07 0.03
Amortization Expense		 -0.49 -0.81 -0.93 -1.11 -1.02 -0.73 -0.42 -0.42 -0.29 -0.15 -0.16
Non-Cash Adjustments To Reconcile Net Income		 3.78 2.25 2.44 5.99 2.69 2.39 2.46 2.54 2.53 9.40 1.99
Changes in Operating Assets and Liabilities, net		 1.24 3.93 -4.57 0.22 2.48 -0.82 -5.26 -0.81 -1.68 -0.99 -3.05
Net Cash From Investing Activities		 -38 12 -14 0.74 2.19 28 8.55 -59 8.59 -2.89 20
Net Cash From Continuing Investing Activities		 -38 12 -14 0.74 2.19 28 8.55 -59 8.59 -2.89 20
Purchase of Investments		 -46 -16 -52 -40 -28 -2.99 -23 -90 -15 -36 0.00
Sale of Property, Plant & Equipment		 - - 0.00 0.04 0.05 0.01 0.01 0.01 0.00 0.00 0.00
Sale and/or Maturity of Investments		 8.25 28 39 41 30 31 32 31 24 33 20
Net Cash From Financing Activities		 72 -0.05 4.13 21 -0.25 0.29 0.03 -0.12 0.13 -0.20 -0.19
Net Cash From Continuing Financing Activities		 72 -0.05 4.13 21 -0.25 0.29 0.03 -0.12 0.13 -0.20 -0.19
Other Financing Activities, net		 - - - - 0.25 0.29 0.03 - 0.13 -0.20 -0.19

Annual Balance Sheets for Black Diamond Therapeutics

This table presents Black Diamond Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 52 158 330 248 156 159 123 143
Total Current Assets		 52 156 320 216 128 134 101 132
Cash & Equivalents		 52 155 35 66 34 56 36 21
Short-Term Investments		 - 0.00 280 144 88 75 62 108
Prepaid Expenses		 0.02 1.05 4.49 5.92 4.90 2.63 2.60 3.79
Plant, Property, & Equipment, net		 0.13 0.16 0.39 3.04 2.59 1.73 1.39 0.37
Total Noncurrent Assets		 0.01 2.42 9.73 29 26 23 20 10
Other Noncurrent Operating Assets		 0.01 2.42 9.73 29 26 23 20 10
Total Liabilities & Shareholders' Equity		 52 158 330 248 156 159 123 143
Total Liabilities		 6.60 4.88 22 52 41 42 39 31
Total Current Liabilities		 2.58 4.86 14 24 15 20 21 16
Accounts Payable		 2.12 1.96 2.54 4.11 1.88 2.32 4.01 0.58
Accrued Expenses		 0.45 2.90 12 20 13 17 17 15
Total Noncurrent Liabilities		 4.02 0.02 7.69 28 25 22 19 15
Other Noncurrent Operating Liabilities		 4.02 0.02 7.69 28 25 22 19 15
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -16 -47 308 196 116 117 83 112
Total Preferred & Common Equity		 -16 -47 308 196 116 117 83 112
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -16 -47 308 196 116 117 83 112
Common Stock		 0.17 3.81 425 440 453 534 570 577
Retained Earnings		 -16 -51 -118 -244 -335 -417 -487 -465
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 0.61 -0.41 -1.82 -0.03 0.02 0.10

Quarterly Balance Sheets for Black Diamond Therapeutics

This table presents Black Diamond Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 172 143 150 138 176 166 158 133
Total Current Assets		 147 119 127 116 156 147 139 123
Cash & Equivalents		 58 25 33 23 98 30 31 30
Short-Term Investments		 86 90 90 89 54 113 105 88
Prepaid Expenses		 2.79 3.61 3.78 2.86 3.28 3.90 3.49 4.71
Plant, Property, & Equipment, net		 1.82 1.64 1.56 1.47 1.30 1.21 1.13 0.34
Total Noncurrent Assets		 24 22 22 21 19 18 18 9.62
Other Noncurrent Operating Assets		 24 22 22 21 19 18 18 9.62
Total Liabilities & Shareholders' Equity		 172 143 150 138 176 166 158 133
Total Liabilities		 38 38 39 40 35 34 32 29
Total Current Liabilities		 15 17 18 21 17 17 16 15
Accounts Payable		 0.69 1.18 0.76 1.97 2.63 0.77 0.98 2.97
Accrued Expenses		 14 16 18 19 14 16 15 12
Total Noncurrent Liabilities		 23 21 21 20 18 17 16 14
Other Noncurrent Operating Liabilities		 23 21 21 20 18 17 16 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 134 104 111 97 142 133 126 104
Total Preferred & Common Equity		 134 104 111 97 142 133 126 104
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 134 104 111 97 142 133 126 104
Common Stock		 533 540 567 568 572 574 576 578
Retained Earnings		 -398 -436 -456 -471 -431 -441 -450 -474
Accumulated Other Comprehensive Income / (Loss)		 -0.36 -0.10 -0.12 0.11 -0.02 -0.03 0.14 -0.04

Annual Metrics And Ratios for Black Diamond Therapeutics

This table displays calculated financial ratios and metrics derived from Black Diamond Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 35,995,660.00 36,228,856.00 36,366,206.00 51,635,184.00 56,585,063.00 56,974,913.00
DEI Adjusted Shares Outstanding		 0.00 0.00 35,995,660.00 36,228,856.00 36,366,206.00 51,635,184.00 56,585,063.00 56,974,913.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.80 -3.47 -2.51 -1.60 -1.23 0.39
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -301.21% -94.88% -82.21% 29.02% 5.34% 11.52% 123.04%
EBIT Growth		 0.00% -299.77% -99.60% -81.03% 29.53% 7.24% 14.83% 125.48%
NOPAT Growth		 0.00% -229.43% -137.18% -82.37% 26.83% 6.86% 8.88% 122.71%
Net Income Growth		 0.00% -361.14% -63.30% -86.75% 27.41% 9.57% 15.48% 132.10%
EPS Growth		 0.00% -284.39% 87.93% -69.27% 27.38% 25.40% 32.45% 130.71%
Operating Cash Flow Growth		 0.00% -191.86% -111.34% -92.05% 15.04% 21.59% 6.62% 147.53%
Free Cash Flow Firm Growth		 0.00% 0.00% -65.82% -92.86% 12.74% 26.18% -2.93% 125.08%
Invested Capital Growth		 0.00% 80.57% -484.72% -89.99% 48.78% -106.19% -4.27% -7.53%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -20.52% -3.95% 6.90% -1.38% 4.16% 4.88%
EBIT Q/Q Growth		 0.00% 0.00% -23.50% -2.04% 7.10% -0.27% 4.24% 1.38%
NOPAT Q/Q Growth		 0.00% 0.00% -22.63% -2.34% 4.36% 1.14% 3.17% 5.61%
Net Income Q/Q Growth		 0.00% 0.00% 13.34% -19.41% 4.99% 1.99% 4.68% 4.04%
EPS Q/Q Growth		 0.00% 0.00% 66.12% -2.36% 4.55% 11.74% 4.51% 8.33%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -18.90% -9.00% 2.42% 10.69% -1.80% 38.73%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -7.57% 1.77% 14.88% -5.59% 129.72%
Invested Capital Q/Q Growth		 0.00% 0.00% -27.62% 13.54% 35.05% -47.54% -0.22% -75.82%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24.79%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 17.89%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.15%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 31.95%
Tax Burden Percent		 100.00% 116.81% 100.00% 100.00% 102.53% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.96% 98.71% 94.33% 97.32% 97.77% 97.72% 96.96% 122.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -19.75% -41.47% -29.17% -49.87% -58.52% -70.94% -69.67% 22.88%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.78%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.84%
Return on Common Equity (ROCE)		 6.79% 13.09% -16.48% -49.87% -58.52% -70.94% -69.67% 22.88%
Return on Equity Simple (ROE_SIMPLE)		 57.46% 87.33% -21.85% -64.11% -78.80% -70.62% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.23 -21 -49 -89 -65 -61 -55 13
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 17.89%
Net Nonoperating Expense Percent (NNEP)		 -5.22% -20.02% -7.90% -14.02% -15.75% -17.25% -12.64% 8.67%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -51.85% -66.21% 11.16%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 23.67%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 47.94%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 82.11%
Earnings before Interest and Taxes (EBIT)		 -8.94 -36 -71 -129 -91 -84 -72 18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.89 -36 -70 -127 -90 -85 -75 17
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.75 0.99 0.57 1.24 1.45 1.23
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.75 0.99 0.57 1.24 1.45 1.23
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.98
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.19
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.16%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.14
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.56
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.54
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.78
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.33
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.72
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.14 -1.04 -1.02 -1.04 -1.07 -1.09 -1.15 -1.16
Leverage Ratio		 1.15 1.06 1.06 1.15 1.30 1.35 1.41 1.36
Compound Leverage Factor		 1.15 1.04 1.00 1.12 1.27 1.32 1.36 1.66
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 134.36% 130.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -34.36% -30.74% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 18.43 24.68 31.49 0.07 -3.09 -2.49 -4.86 0.04
Noncontrolling Interest Sharing Ratio		 134.36% 131.56% 43.49% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 20.07 32.02 22.48 9.12 8.37 6.82 4.92 8.42
Quick Ratio		 20.06 31.80 22.16 8.87 8.05 6.69 4.79 8.18
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -26 -43 -82 -72 -53 -55 14
Operating Cash Flow to CapEx		 -11,123.68% -117,495.24% -36,722.54% -3,695.50% -46,492.90% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -42,640.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -52,146.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -52,288.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.53
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 79.91
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -6.43 -1.25 -7.31 -14 -7.11 -15 -15 -16
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -4.41
Increase / (Decrease) in Invested Capital		 0.00 5.18 -6.06 -6.58 6.77 -7.55 -0.63 -1.15
Enterprise Value (EV)		 210 247 839 -17 -57 14 23 9.80
Market Capitalization		 201 201 1,154 193 65 145 121 138
Book Value per Share		 ($7.70) ($22.72) $8.55 $5.41 $3.18 $2.26 $1.47 $1.97
Tangible Book Value per Share		 ($7.70) ($22.72) $8.55 $5.41 $3.18 $2.26 $1.47 $1.97
Total Capital		 45 153 308 196 116 117 83 112
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -52 -155 -315 -210 -123 -131 -99 -129
Capital Expenditures (CapEx)		 0.08 0.02 0.14 2.71 0.18 -0.06 -0.09 -0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.55 -3.82 -9.73 -18 -10 -17 -18 -12
Debt-free Net Working Capital (DFNWC)		 49 151 305 192 112 114 81 117
Net Working Capital (NWC)		 49 151 305 192 112 114 81 117
Net Nonoperating Expense (NNE)		 2.70 21 19 37 26 22 15 -9.85
Net Nonoperating Obligations (NNO)		 -52 -155 -315 -210 -123 -131 -99 -129
Total Depreciation and Amortization (D&A)		 0.04 0.05 1.78 2.39 1.04 -0.74 -3.44 -0.95
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -17.06%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 166.73%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 166.73%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 ($4.42) ($16.99) ($2.05) ($3.47) ($2.52) ($1.88) ($1.27) $0.39
Adjusted Weighted Average Basic Shares Outstanding		 2.02M 35.91M 36.14M 36.19M 36.33M 43.95M 55.03M 56.87M
Adjusted Diluted Earnings per Share		 ($4.42) ($16.99) ($2.05) ($3.47) ($2.52) ($1.88) ($1.27) $0.39
Adjusted Weighted Average Diluted Shares Outstanding		 2.02M 35.91M 36.14M 36.19M 36.33M 43.95M 55.03M 57.56M
Adjusted Basic & Diluted Earnings per Share		 ($4.42) ($16.99) ($2.05) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.02M 2.08M 32.91M 36.27M 36.48M 51.72M 56.66M 57.29M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.23 -21 -49 -89 -65 -61 -55 14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19.87%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 31.95%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -71,294.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -48,699.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -71,436.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -48,841.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Black Diamond Therapeutics

This table displays calculated financial ratios and metrics derived from Black Diamond Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 51,575,323.00 51,635,184.00 51,717,849.00 56,252,794.00 56,504,895.00 56,585,063.00 56,662,222.00 56,862,635.00 56,935,279.00 56,974,913.00 57,288,750.00
DEI Adjusted Shares Outstanding		 51,575,323.00 51,635,184.00 51,717,849.00 56,252,794.00 56,504,895.00 56,585,063.00 56,662,222.00 56,862,635.00 56,935,279.00 56,974,913.00 57,288,750.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.45 -0.38 -0.35 -0.35 -0.28 -0.28 1.00 -0.19 -0.15 -0.27 -0.16
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Growth		 -8.30% -6.01% 7.33% -9.39% 28.61% 15.98% 382.22% 43.83% 41.98% 4.69% -118.33%
EBIT Growth		 -5.54% -1.16% 12.26% -3.46% 31.45% 16.13% 396.61% 42.67% 39.89% 1.51% -117.98%
NOPAT Growth		 -8.53% 4.56% 6.10% -10.47% 24.50% 12.37% 484.77% 39.36% 39.45% 3.64% -114.45%
Net Income Growth		 -6.25% 7.92% 12.69% -3.95% 32.38% 17.64% 410.24% 46.95% 45.38% 5.44% -115.98%
EPS Growth		 25.00% 42.37% 38.60% 30.77% 37.78% 17.65% 380.00% 47.22% 46.43% 10.71% -116.33%
Operating Cash Flow Growth		 -11.45% 36.39% -5.83% -2.49% 38.33% -7.87% 351.95% 37.80% 30.67% 54.92% -119.16%
Free Cash Flow Firm Growth		 13.48% 68.07% 50.54% 28.56% 58.62% -72.66% 744.82% -2.36% -84.29% 8.14% -108.82%
Invested Capital Growth		 9.23% -106.19% -110.45% -63.07% -53.50% -4.27% 0.08% 14.49% 38.71% -7.53% -28.24%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -21.81% 14.12% 3.67% -8.54% 20.50% -1.08% 423.55% -121.60% 17.88% -66.02% 37.78%
EBIT Q/Q Growth		 -19.07% 15.84% 4.41% -8.01% 21.11% -2.97% 438.05% -120.88% 17.27% -68.70% 38.29%
NOPAT Q/Q Growth		 -19.87% 13.15% 2.92% -9.31% 18.08% -0.80% 526.27% -117.23% 18.20% -60.41% 36.06%
Net Income Q/Q Growth		 -20.13% 15.64% 6.10% -9.24% 21.86% -2.75% 453.72% -118.68% 19.53% -77.88% 40.22%
EPS Q/Q Growth		 13.46% 24.44% -2.94% -2.86% 22.22% 0.00% 450.00% -119.39% 21.05% -66.67% 36.00%
Operating Cash Flow Q/Q Growth		 -27.80% 24.00% -51.90% 30.53% 23.11% -32.96% 454.77% -117.15% 14.29% 13.54% -50.76%
Free Cash Flow Firm Q/Q Growth		 -17.13% 60.46% -19.99% -28.55% 32.16% -64.99% 548.12% -120.41% -22.15% 17.76% 56.99%
Invested Capital Q/Q Growth		 -35.63% -47.54% 25.72% -9.70% -27.67% -0.22% 28.82% 6.11% 8.49% -75.82% 15.10%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 79.46% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 77.90% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 79.92% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 80.77% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.13% 98.36% 96.62% 97.72% 96.79% 96.59% 101.06% 90.43% 87.95% 92.74% 89.83%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -62.88% -70.94% -78.81% -83.38% -63.09% -69.67% 4.14% 11.85% 19.23% 22.88% -35.16%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 35.10% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 35.48% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -62.88% -70.94% -78.81% -83.38% -63.09% -69.67% 4.14% 11.85% 19.23% 22.88% -35.16%
Return on Equity Simple (ROE_SIMPLE)		 -62.62% 0.00% -76.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -17 -15 -14 -15 -13 -13 55 -9.39 -7.68 -12 -7.88
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 77.90% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.30% -3.78% -3.71% -4.16% -2.23% -2.78% 1.50% -0.88% -0.66% -2.45% -0.85%
Return On Investment Capital (ROIC_SIMPLE)		 - -12.51% -13.59% -13.95% -13.03% -15.36% 38.53% -7.08% -6.09% -10.99% -7.56%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.09% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 15.01% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 22.10% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -23 -20 -19 -20 -16 -17 56 -12 -9.66 -16 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -20 -20 -21 -17 -17 56 -12 -9.87 -16 -10
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.10 1.24 2.51 2.36 2.52 1.45 0.62 1.06 1.71 1.23 1.17
Price to Tangible Book Value (P/TBV)		 1.10 1.24 2.51 2.36 2.52 1.45 0.62 1.06 1.71 1.23 1.17
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 1.25 2.01 3.08 1.98 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 17.25 9.77 10.04 6.19 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.80% 10.24% 9.96% 16.16% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.15 0.14 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.85 0.56 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.45 0.54 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.77 0.78 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.76 0.33 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.49 0.72 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.08 -1.09 -1.08 -1.10 -1.11 -1.15 -1.09 -1.09 -1.11 -1.16 -1.10
Leverage Ratio		 1.32 1.35 1.37 1.40 1.34 1.41 1.30 1.30 1.32 1.36 1.26
Compound Leverage Factor		 1.29 1.33 1.33 1.36 1.30 1.36 1.31 1.17 1.16 1.26 1.13
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.43 -1.15 0.26 0.20 -0.70 -3.37 0.49 -0.08 1.29 -0.76 -1.70
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.76 6.82 7.05 6.87 5.55 4.92 9.24 8.73 8.94 8.42 8.46
Quick Ratio		 9.57 6.69 6.84 6.67 5.42 4.79 9.05 8.50 8.72 8.18 8.14
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -7.05 -8.46 -11 -7.37 -12 55 -11 -14 -11 -4.81
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.44 0.44 0.47 0.53 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 47.55 50.51 53.85 79.91 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -9.94 -15 -11 -12 -15 -15 -11 -10 -9.35 -16 -14
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 -6.43 -6.32 -5.69 -4.41 0.00
Increase / (Decrease) in Invested Capital		 1.01 -7.55 -5.72 -4.62 -5.32 -0.63 0.01 1.73 5.91 -1.15 -3.07
Enterprise Value (EV)		 3.77 14 147 139 133 23 -65 -1.81 80 9.80 3.77
Market Capitalization		 148 145 262 262 246 121 88 141 216 138 122
Book Value per Share		 $2.60 $2.26 $2.02 $1.97 $1.72 $1.47 $2.50 $2.33 $2.22 $1.97 $1.82
Tangible Book Value per Share		 $2.60 $2.26 $2.02 $1.97 $1.72 $1.47 $2.50 $2.33 $2.22 $1.97 $1.82
Total Capital		 134 117 104 111 97 83 142 133 126 112 104
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -144 -131 -115 -123 -113 -99 -152 -143 -136 -129 -118
Capital Expenditures (CapEx)		 0.00 0.00 0.00 -0.04 -0.05 -0.01 -0.01 -0.01 -0.00 -0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -17 -13 -15 -18 -18 -14 -13 -12 -12 -9.83
Debt-free Net Working Capital (DFNWC)		 132 114 102 108 95 81 139 130 123 117 108
Net Working Capital (NWC)		 132 114 102 108 95 81 139 130 123 117 108
Net Nonoperating Expense (NNE)		 6.20 4.81 4.05 4.42 2.87 3.19 -2.01 1.17 0.81 2.79 1.15
Net Nonoperating Obligations (NNO)		 -144 -131 -115 -123 -113 -99 -152 -143 -136 -129 -118
Total Depreciation and Amortization (D&A)		 -0.38 -0.73 -0.85 -1.02 -0.93 -0.64 -0.33 -0.34 -0.21 -0.08 -0.14
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -19.38% -18.44% -17.22% -17.06% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 198.33% 185.60% 176.35% 166.73% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 198.33% 185.60% 176.35% 166.73% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.45) ($0.34) ($0.35) ($0.36) ($0.28) ($0.28) $1.00 ($0.19) ($0.15) ($0.27) ($0.16)
Adjusted Weighted Average Basic Shares Outstanding		 50.94M 43.95M 51.81M 55.16M 56.51M 55.03M 56.66M 56.80M 56.93M 56.87M 57.23M
Adjusted Diluted Earnings per Share		 ($0.45) ($0.34) ($0.35) ($0.36) ($0.28) ($0.28) $0.98 ($0.19) ($0.15) ($0.25) ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding		 50.94M 43.95M 51.81M 55.16M 56.51M 55.03M 57.67M 56.80M 56.93M 57.56M 57.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 51.64M 51.72M 56.25M 56.50M 56.59M 56.66M 56.86M 56.94M 56.97M 57.29M 57.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -15 -14 -15 -13 -13 38 -9.39 -7.68 -12 -7.88
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 54.53% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 80.77% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Black Diamond Therapeutics (NASDAQ: BDTX) continues to operate like a classic clinical-stage biotech: no product revenue, recurring operating losses, and heavy reliance on its balance sheet and investment portfolio to fund research.

Bottom line: The company remains well-capitalized for now, but it is still burning cash and has not yet shown revenue-generating traction. The most recent quarter was somewhat better on the cash burn front than prior periods, but the business is still far from profitability.

  • Strong liquidity position: As of Q1 2026, BDTX had about $30.1 million in cash and $88.2 million in short-term investments, or roughly $118.3 million in near-term liquidity.
  • Quarterly cash balance improved: Cash and equivalents rose from $19.7 million at the end of Q4 2025 to $30.1 million in Q1 2026.
  • Operating cash burn improved sequentially: Net cash used in operations narrowed to $10.2 million in Q1 2026 from $6.8 million in Q4 2025 and $7.9 million in Q3 2025, showing some stabilization.
  • Investment income helped offset losses: In Q1 2026, the company generated $1.0 million of interest and investment income plus $1.2 million of other income.
  • Balance sheet remains solvent: Total assets of $132.9 million still comfortably exceed total liabilities of $28.6 million.
  • Equity base is still solid: Total common equity was $104.3 million at the end of Q1 2026.
  • No revenue yet: BDTX reported $0 in revenue in Q1 2026, consistent with its pre-commercial biotech stage.
  • R&D spending remains elevated: Research and development expense was $7.0 million in Q1 2026, slightly higher than the prior quarter’s $6.3 million, which is expected for a development-stage company but keeps losses high.
  • Large investment portfolio movements: The company sold $19.5 million of investments in Q1 2026, which boosted liquidity but also shows dependence on portfolio assets to fund operations.
  • Share count has been fairly stable recently: Weighted average diluted shares were roughly 57.2 million in Q1 2026, not a major jump from the prior quarter.
  • Still losing money: BDTX posted a net loss of $9.0 million in Q1 2026, versus $15.1 million in Q4 2025 and $8.5 million in Q3 2025.
  • Operating losses remain substantial: Operating loss was $11.3 million in Q1 2026, reflecting a business that is still pre-commercial and highly expense-driven.
  • Retained losses continue to accumulate: Retained earnings stood at negative $473.8 million in Q1 2026, underscoring the long history of losses.
  • Cash is being consumed: Even with a healthier quarter, the company still used $10.2 million of cash from operations in Q1 2026, which means the balance sheet will keep eroding unless clinical progress improves or financing is raised.
  • No sign of profitability yet: Quarterly operating expenses of $11.3 million were far above revenue, and there is no evidence yet that the company is close to breaking even.

Looking at the broader trend over the last four years, BDTX’s pattern is clear: the company has periodically raised capital and used its investment portfolio to fund ongoing R&D, while net losses have remained persistent. The good news is that liquidity is still ample today. The risk is that, without a commercial product or a meaningful clinical catalyst, the company may eventually need to tap capital markets again.

For retail investors, BDTX remains a high-risk, catalyst-driven biotech. The latest quarter shows balance sheet strength and manageable near-term liquidity, but the lack of revenue and ongoing cash burn mean the stock still depends heavily on pipeline execution.

07/28/26 03:49 AM ETAI Generated. May Contain Errors.

Black Diamond Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Black Diamond Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Over the last 7 years, Black Diamond Therapeutics' net income changed from -$8.93 million in 2018 to $22.37 million in 2025, a change of -350.4%. Find out what analysts predict for Black Diamond Therapeutics in the coming months.

Black Diamond Therapeutics' total operating income in 2025 was $12.52 million, based on the following breakdown:
  • Total Gross Profit: $70 million
  • Total Operating Expenses: $57.48 million

Over the last 7 years, Black Diamond Therapeutics' total revenue changed from $0.00 in 2018 to $70 million in 2025, a change of 7,000,000,000.0%.

Black Diamond Therapeutics' total liabilities were at $30.80 million at the end of 2025, a 21.7% decrease from 2024, and a 366.8% increase since 2018.

In the past 7 years, Black Diamond Therapeutics' cash and equivalents has ranged from $20.99 million in 2025 to $154.67 million in 2019, and is currently $20.99 million as of their latest financial filing in 2025.

Over the last 7 years, Black Diamond Therapeutics' book value per share changed from -7.70 in 2018 to 1.97 in 2025, a change of -125.6%.


Related Companies

Financial statements for NASDAQ:BDTX last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
The 1974 Kissinger "Secret" Wall Street Never Decoded
In 1974, Henry Kissinger helped create the U.S.-Saudi Arabia Joint Commission on Economic Cooperation - a litt...
Golden Portfolio | Sponsoredtc pixel
What Elon told his top shareholders in Texas
Late last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...
Banyan Hill Publishing | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
A storm is coming
The U.S. dollar has sunk to near a four-year low, while the Bureau of Economic Analysis prepares a change to h...
Stansberry Research | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel